Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

DIABETES

Delaying diabetes onset

N. Engl. J. Med. 381, 603–613 (2019)

The onset of type 1 diabetes can be delayed in individuals who are genetically at risk by using an anti-immune therapy.

Type 1 diabetes is caused by the autoimmune destruction of insulin-producing cells, which results in hyperglycemia, leading affected individuals to become dependent on lifelong insulin therapy. Immune interventions aim to prevent the loss of β-cells and progression to full type 1 diabetes. One such therapy is teplizumab, a monoclonal antibody.

In a clinical trial of 76 participants who were genetically at risk of developing type 1 diabetes, those given teplizumab developed type 1 diabetes on average over 2 years later than those given a placebo.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hannah Stower.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stower, H. Delaying diabetes onset. Nat Med 25, 1798 (2019). https://doi.org/10.1038/s41591-019-0681-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-019-0681-2

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing